I Ebola / HIV / flu / study Prostate Cancer Therapeutic 2Q / hepatitis B / Lung Cancers Therapeutic 4Q / CIN / innovative cancer / neck cancer / head and neck cancer / hepatitis / influenza / pre-cancerous cervical disease / cancers / hTERT DNA cancer / tumor / H1N1 influenza / cancer / tumors / disease / Ebola / HPV / pandemic flu / I hepatitis B / diseases / infectious diseases / infectious disease / /
MedicalTreatment
immunotherapies / immunotherapy / /
Organization
National Institute of Health / Princeton University / University of Pennsylvania Synthetic / Scientific Advisory Board / George Mason University / Fred Hutchinson Cancer Research Center / /
Person
Nancy Wysenski / Scott M. White / Ex-Merck Peter Kies / J. Joseph Kim / Stanley A. Plotkin / Ex-Ernst / Anthony Ford-Hutchinson / Niranjan Y. Sardesai / Vaccines Angel Cabrera / David B. Weiner / Morton Collins / Simon X. Benito / Mark Gelder / Adel Mahmoud / Wistar / Avtar Dhillon / L. Bagarazzi / Philip D. Greenberg / / /
Position
Chief Financial Officer / Professor / Dept. Molecular Biology / President / SVP / Chairman Professor / Pharmaceuticals Contact Bernie Hertel VP / Investor Relations & Communications / Chief Operating Officer / Chief Medical Officer / CEO / Vice President / Clinical Development / President and Chief Executive Officer / COO / Pre-clinical Cervical Dysplasia Therapeutic Head / VP / Clinical Development / Chairman of the Board / Professor / board member / /
Inovio. Revolutionizing the fight against cancer and infectious diseases. Inovio’s DNA-based immunotherapy technology achieved a ground-breaking milestone for the field, achieving clinically